At AAO 2026 Retina Subspecialty Day, SriniVas Sadda, MD, outlined limits of current GA growth metrics and introduced border ...
The concerns of October 10, 1857, sound remarkably familiar today.
Teprotumumab N01 injection (SYCUME, IBI311; Innovent Biologics) met the primary end point of the phase 3 RESTORE-3 trial in inactive thyroid eye disease, according to a company announcement.¹ At week ...
At the American Academy of Ophthalmology (AAO) 2026 Retina Subspecialty Day in New Orleans, Charles C. Wykoff, MD, PhD, ...
Stuart Therapeutics Inc. submitted an investigational NDA amendment to the FDA to study ST-100 (vezocolmitide) in corneal ...
There is still a lot to be learned about the complicated relationship between blood pressure (BP) and glaucoma, and it has taken a while to amass the body of knowledge available today. Some of the ...
The underlying field was recognized this week when the 2026 Nobel Prize in Physiology or Medicine went to Karl Deisseroth, MD ...
Michel Michaelides, MD, discusses phase 3 DRAGON results showing that oral tinlarebant slowed atrophic lesion growth by about ...
Thomas V. Johnson III, MD, PhD, the Shelley and Allan Holt Rising Professor of Ophthalmology at the Wilmer Eye Institute at Johns Hopkins University School of Medicine in Baltimore, Maryland, was ...
Paul Nderitu, MBChB, MPhil, MBCS, FRCOphth, PhD, gives an update at EURETINA 2026 on Global RETFound, a foundation model ...
The American Academy of Ophthalmology (AAO) returns to New Orleans from October 9-12 for AAO 2026, with more than 20,000 ...
Cataract original papers on intracameral antibiotics and IOL power, a guideline-based case symposium, and ocular surface ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results